MindWalk signs multi-year AI drug discovery agreement with Teva Australia

HYFT•2026-11-04

MindWalk signed a multi-year agreement with Teva Australia to deploy its ReefIQ platform for a defined scope of antibody-discovery work, extending a collaboration that began in 2018.

MindWalk signs multi-year AI drug discovery agreement with Teva Australia

1. Agreement extends collaboration

Related News

Prison operators fall after Democrats sweep Congress

Actuate Therapeutics plans Phase 1/2 trial of oral elraglusib for Q1 2027

Democratic sweep positive for US credit rating outlook, Scope Ratings says

UroGen Pharma Q3 revenue misses expectations on JELMYTO decline

ImmunityBio partners with Accord Healthcare, Uniphar to expand ANKTIVA access in Europe